PARP1 and early-onset autosomal dominant Alzheimer disease: PARP1 is primarily identified as a target in oncology yet recent studies have also suggested it as a potential target against ageing and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease [24, 25, 26].